Next Article in Journal
Previous Article in Journal
Previous Article in Special Issue
Vaccines 2014, 2(2), 463-499; doi:10.3390/vaccines2020463
Review

Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations

1,* , 1
, 1
, 2
, 1
 and 2,*
Received: 13 February 2014; in revised form: 24 April 2014 / Accepted: 6 May 2014 / Published: 16 June 2014
(This article belongs to the Special Issue Tuberculosis Vaccines)
View Full-Text   |   Download PDF [723 KB, uploaded 16 June 2014]
Abstract: Novel efficient vaccines are needed to control tuberculosis (TB), a major cause of morbidity and mortality worldwide. Several TB vaccine candidates are currently in clinical and preclinical development. They fall into two categories, the one of candidates designed as a replacement of the Bacille Calmette Guérin (BCG) to be administered to infants and the one of sub-unit vaccines designed as booster vaccines. The latter are designed as vaccines that will be administered to individuals already vaccinated with BCG (or in the future with a BCG replacement vaccine). In this review we provide up to date information on novel tuberculosis (TB) vaccines in development focusing on the risk assessment of candidates composed of genetically modified organisms (GMO) which are currently evaluated in clinical trials. Indeed, these vaccines administered to volunteers raise biosafety concerns with respect to human health and the environment that need to be assessed and managed.
Keywords: tuberculosis; vaccine candidate; clinical trial; genetically modified organism; risk assessment; biosafety tuberculosis; vaccine candidate; clinical trial; genetically modified organism; risk assessment; biosafety
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Leunda, A.; Baldo, A.; Goossens, M.; Huygen, K.; Herman, P.; Romano, M. Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations. Vaccines 2014, 2, 463-499.

AMA Style

Leunda A, Baldo A, Goossens M, Huygen K, Herman P, Romano M. Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations. Vaccines. 2014; 2(2):463-499.

Chicago/Turabian Style

Leunda, Amaya; Baldo, Aline; Goossens, Martine; Huygen, Kris; Herman, Philippe; Romano, Marta. 2014. "Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations." Vaccines 2, no. 2: 463-499.

Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert